secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001636282-25-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.
- Net loss of $44.8M for Q1 2025 vs. $43.9M in Q1 2024; R&D expenses rose to $41.6M.
- Extended Phase 1 data for SPY001 supports potential quarterly or biannual dosing; Phase 2 initiation planned mid-2025.
- Interim Phase 1 data for SPY002 expected Q2 2025; first participant dosed in Phase 1 trial of SPY003.
- Plan to initiate Phase 2 trials in UC and RA mid-2025 with 7+ proof-of-concept readouts in 2026-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/0001636282-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/syre-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001636282-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer